Abstract:Importance: Lynch syndrome is caused by dominantly inherited germline mutations that predispose individuals to colorectal, endometrial, ovarian, and other cancers through inactivation of the cellular mismatch repair system. Lynch syndrome–associated cancers are amenable to surveillance strategies that may improve survival. The age at which surveillance should start is disputed.Objective: To determine whether mutated gene and type of mutation influence age at onset of Lynch syndrome–associated cancers.Design, Setting, and Participants: A retrospective cohort study of individuals with Lynch syndrome–associated colorectal, endometrial, and/or ovarian cancers whose medical records were included in the clinical database of a large quaternary referral center for genomic medicine in the Northwest of England.Exposures: Mutated gene (MLH1, MSH2, MSH6, and/or PMS2) and type of mutation (truncating, splicing, or large rearrangement).Main Outcomes and Measures: Age at cancer diagnosis.Results: A total of 1063 individuals with proven Lynch syndrome were included, 495 male and 568 female (mean age 52 years; age range, 10-93 years [children were included in the database, but no children developed cancer]). There were 546 men and women with colorectal cancer, 162 women with endometrial cancer, and 49 women with ovarian cancer; mean follow-up was 68.2 months. Among MLH1 mutation carriers, mutations in MLH1 were associated with colorectal cancer in 249 (61%) of 409 men and women; endometrial cancer in 53 of 196 (27%) women; and ovarian cancer in 15 (8%) of 196 women. Among MSH2 mutation carriers, mutations in MSH2 (the most prevalent mutations overall) were most commonly associated with female-specific cancers: endometrial cancer in 83 (30%) of 279 women; ovarian cancer in 28 (10%) of 279 women; and colorectal cancer in 239 (50%) 479 men and women. Mutations in MSH6 were less prevalent, and MSH6 mutation carriers presented with colorectal and endometrial cancer at later ages than carriers of mutations in MSH2 or MLH1. When stratified by mutation type, women with truncating MLH1 mutations had later ages of onset of endometrial cancer than those with nontruncating mutations (median difference, 6.6 years; 95% CI, 2.7-10.4; P = .002). Carriers of truncating MLH1 mutations presented with colorectal cancer at later ages than those with other mutations, but the difference was not statistically significant.Conclusions and Relevance: Individuals with known Lynch syndrome could be risk stratified by mutated gene and mutation type in tailored surveillance programs. Specifically, individuals with MSH6 mutations could be offered cancer surveillance from a later age. Furthermore, those with truncating MLH1 mutations could begin endometrial cancer surveillance later than those with nontruncating mutations.

Risks of Lynch syndrome cancers for MSH6 mutation carriers

Cancer Risks for PMS2-Associated Lynch Syndrome.

Estimating cancer risk in carriers of Lynch syndrome variants in UK Biobank

Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database

Associations of Pathogenic Variants in MLH1, MSH2, and MSH6 With Risk of Colorectal Adenomas and Tumors and With Somatic Mutations in Patients With Lynch Syndrome

Early age of onset and broad cancer spectrum persist in MSH6- and PMS2-associated Lynch syndrome

Lower degree of microsatellite instability in colorectal carcinomas from MSH6-associated Lynch syndrome patients

Mortality by age, gene and gender in carriers of pathogenic mismatch repair gene variants receiving surveillance for early cancer diagnosis and treatment: a report from the prospective Lynch syndrome database

Germline Mutations in Chinese Colorectal Cancer Patients with Mismatch Repair Deficiency.

Association of Mismatch Repair Mutation With Age at Cancer Onset in Lynch Syndrome

PMS2 monoallelic mutation carriers: the known unknown

The Prevalence of Germline Mutations in Chinese Colorectal Cancer Patients with Mismatch Repair Deficiency.

The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations

Identification of Lynch syndrome among patients with colorectal cancer

Delineating genotype and parent‐of‐origin effect on the phenotype in MSH6‐associated Lynch syndrome

Risk of Gastric and Small Intestinal Cancer in Patients With Lynch syndrome – Data From a Large, Community-Based U.S. Population

Cancer risks in Lynch syndrome, Lynch-like syndrome, and familial colorectal cancer type X: a prospective cohort study

Breast carcinoma and Lynch syndrome: molecular analysis of tumors arising in mutation carriers, non-carriers, and sporadic cases

Characteristics of Cancer in Subjects Carrying Lynch Syndrome-Associated Gene Variants in Taiwanese Population: A Hospital-Based Study in Taiwan

Aspirin, Ibuprofen, and the Risk of Colorectal Cancer in Lynch Syndrome

Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch Syndrome